FDA Partners
FDA Partners
  • HOME
  • SERVICES
    • FOR COMPANIES
    • FOR INVESTORS
  • ABOUT
  • OUR TEAM
  • More
    • HOME
    • SERVICES
      • FOR COMPANIES
      • FOR INVESTORS
    • ABOUT
    • OUR TEAM
CONTACT US
  • HOME
  • SERVICES
    • FOR COMPANIES
    • FOR INVESTORS
  • ABOUT
  • OUR TEAM
CONTACT US

SERVICES FOR COMPANIES

With lean Agency reviewer bandwidth and fast-moving policies, companies can’t afford stalled submissions, or fragmented vendors and handoffs.

  
FDA Partners delivers one integrated team to align regulatory strategy, validate clinical evidence, and audit quality systems under one roof, so you stay ready.


THE FDA PARTNERS ADVANTAGE

Stop guessing what the reviewer wants. Ask someone who used to be one.

250+ Years of Combined Experience

We integrate deep interdisciplinary expertise across industry, FDA, and academia to provide strategic regulatory and scientific guidance.

Proven Innovation

Proven Innovation

Proven Innovation

We’ve secured first-ever Alzheimer’s Breakthrough Device Designation, earned marketing authorizations for pioneering AI/ML tools, and authored FDA guidances and training still used today. We don’t just follow the cutting edge; we set it. 

No "B-Teams"

Proven Innovation

Proven Innovation

Unlike large CROs and other advisory firms that hand your project to junior associates, FDA Partners provides direct, daily access to former FDA leaders and subject matter experts. 

CORE CAPABILITIES: END-TO-END SUPPORT

Precision execution from concept to commercialization.

Pre-Submission (Q-Sub) & Pre-IND Strategy and Execution

We maximize the value of the pre-submission (Q-Sub) and pre-IND processes, and the Breakthrough Device Designation (BDD)/Accelerated Review Programs, by developing the FDA strategy and then executing end-to-end: building Target Product Profiles (TPPs) and Data Development Plans (DDPs), preparing the submission package, leading high-impact “Sprint” discussions and FDA meetings, and driving favorable FDA outcomes, documented in finalized meeting minutes. 

510(k) & De Novo Execution

FDA-ready eSTAR submissions with clear predicate/novelty strategy and robust substantial equivalence rationales built to avoid preventable deficiencies and keep review timelines on track. 

Leverage FDA’s Least Burdensome Approach

Smartly complete value-added activities to minimize FDA regulatory requirements and clinical burdens to secure marketing approvals.  

US Market Entry

Bridging international development data (Europe/Asia) to meet stringent FDA requirements. 

Regulatory Due Diligence

FDA-ready eSTAR submissions with clear predicate/novelty strategy and robust substantial equivalence rationales built to avoid preventable deficiencies and keep review timelines on track. 

Clinical Evidence Strategy

We design "totality of evidence" narratives, leveraging any existing Real-World Data/Evidence (RWD/RWE) to satisfy modern evidentiary standards.

Integrated Clinical Execution:

End-to-end study design, data management, and site monitoring for clinical studies.

Inspection Readiness

We don't just help you prepare; we help you survive the audit. We conduct rigorous mock inspections (on-site + virtual) and readiness assessments for Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP), to ensure your data and sites are compliant.

Quality Management System Requirements (QMSR) & Compliance

We build and remediate QMSR and ISO 13485 conforming systems tailored to your stage, ensuring you are scalable and audit-ready without unnecessary burden. 

ENTERING THE U.S. MARKET

For international biopharma companies entering the U.S. market, we offer targeted pathway and study design support, including regulatory/clinical strategy, RWD/RWE framing, and GCP/GMP readiness - to enable efficient progress today and scalable success over the long term. 

Don't navigate FDA alone.

Partner with the experts who sat on the other side of the table. Contact us to schedule an introductory strategy session with our experts. 

CONTACT US
  • HOME
  • FOR COMPANIES
  • FOR INVESTORS
  • ABOUT
  • OUR TEAM
  • CONTACT US

Copyright © 2026 FDA Partners - All Rights Reserved.

FDA Partners - contact@fda-partners.com

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept